Investor Relations

Company Overview

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company committed to developing transformational precision medicines for patients living with rare neuroendocrine diseases. The Company develops medicines for previously untreatable or undertreated diseases and provides meaningful support for healthcare providers and patients and their families. In addition to commercializing it’s lead asset in North America, Europe and other regions, Rhythm is advancing a broad clinical development program for setmelanotide in rare MC4R pathway diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.